Skip to main content

Fiscal Wizard · Single-issue tearsheet

RGEN / Jun 20, 2026 Run #7179

RGEN

Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Composite verdict

F 26.3 / 100
Bearish setup · Reversal 8 drivers · 3 gates blocking
  • Wedge Pattern
  • Stochastic Cross
  • MA Rejection
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 21st of 57 in Medical Instruments & Supplies

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Neutral 46Mean-reversion Bearish 24

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -74%
Asset value $37.34Earnings power value $8.94Price $132.02

Priced above its no-growth earnings power value ($8.94/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

43.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
OCF to Net Income 0
EBITDA Margin 96
Cash Conversion 0

Technicals Bearish

9.6 / 100

Bearish setup leads (Wedge Pattern, Stochastic Cross, MA Rejection); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Wedge Pattern 18
Stochastic Cross 18
MA Rejection 20

Risk Gates

3 blocking 6 caution

3 guards active, 25 signals gated.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for RGEN.